[FCSC] Fibrocell Science Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.69 Change: -0.06 (-8%)
Ext. hours: Change: 0 (0%)

chart FCSC

Refresh chart

Strongest Trends Summary For FCSC

FCSC is in the long-term down -100% below S&P in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing various treatments for skin diseases and conditions with unmet medical needs. The company, through its proprietary autologous fibroblast technology, Fibrocell, develops biologic solutions and medical applications of azficel-T for restrictive burn scarring and vocal cord scarring conditions; and biologic products for patients with rare genetic skin and tissue disorders. It has collaboration agreements with Intrexon Corporation for using genetically-modified fibroblasts for treating rare and serious skin, and connective tissue diseases; and University of California, Los Angeles to focus on skin-derived stem cells and other ways to convert skin cells to other cell types. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 234.48% Sales Growth - Q/Q246.43% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-48.97% ROE-90.53% ROI
Current Ratio5.79 Quick Ratio5.7 Long Term Debt/Equity Debt Ratio0.27
Gross Margin-407.93% Operating Margin-7871.34% Net Profit Margin-6148.17% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities150 K Cash From Investing Activities-110 K Cash From Operating Activities-4.24 M Gross Profit50 K
Net Profit-8.53 M Operating Profit-6.86 M Total Assets41.18 M Total Current Assets34.93 M
Total Current Liabilities6.03 M Total Debt Total Liabilities18.9 M Total Revenue190 K
Technical Data
High 52 week2.54 Low 52 week1.5 Last close1.74 Last change-0.57%
RSI36.11 Average true range0.08 Beta0.53 Volume94.25 K
Simple moving average 20 days-4.94% Simple moving average 50 days-7.45% Simple moving average 200 days-12.26%
Performance Data
Performance Week-4.4% Performance Month-5.43% Performance Quart-18.31% Performance Half-7.45%
Performance Year-6.45% Performance Year-to-date16% Volatility daily1.83% Volatility weekly4.09%
Volatility monthly8.38% Volatility yearly29.04% Relative Volume107.4% Average Volume110.87 K
New High New Low

News

2019-10-15 17:13:09 | Reata Successfully Completes Neuromuscular Disorder Study

2019-10-15 15:00:00 | SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - DOVA, SRCI, FCSC

2019-10-15 10:56:36 | Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of SRC Energy, Pivotal Software, MAM Software Group, and Fibrocell Science on behalf of Stockholders and Encourages Investors to Contact the Firm

2019-10-15 10:05:33 | Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – PRTO, FCSC, SEMG, UCFC

2019-10-08 15:56:00 | Lifshitz & Miller LLP Announces Investigation of Church & Dwight Co., Fibrocell Science, Inc., MacroGenics, Inc., MINDBODY, Inc., PaySign, Inc., Zebra Technologies Corporation and Zynerbia Pharmaceuticals

2019-09-23 13:15:56 | Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – UCFC, SEMG, ALDR, FCSC

2019-09-19 12:51:50 | SEMG, PVTL, FCSC and AVDR SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

2019-09-18 14:55:00 | SHAREHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Transaction

2019-09-17 19:17:00 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Fibrocell Science, Inc. NASDAQ: FCSC on Behalf of Fibrocell Shareholders and Encourages Fibrocell Investors to Contact the Firm

2019-09-17 17:52:00 | FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC

2019-09-16 17:20:00 | FIBROCELL SCIENCE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2019-09-16 16:17:31 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Fibrocell Science, Inc. to Castle Creek Pharmaceutical Holdings, Inc. is Fair to Shareholders

2019-09-13 13:05:36 | Exton gene and cell therapy company to be sold in $63.3M deal

2019-09-13 08:02:14 | Fibrocell Spikes 60% After Receiving Cash Bid From Castle Creek Pharma

2019-09-12 18:35:00 | Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell

2019-09-12 17:40:07 | Castle Creek Pharmaceutical Holdings to Acquire Fibrocell

2019-08-26 11:26:57 | Fibrocell Science, Inc. NASDAQ:FCSC Has A ROE Of 20%

2019-08-15 07:45:19 | The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

2019-08-14 16:45:00 | Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

2019-07-11 09:44:37 | How Fibrocell Science, Inc. NASDAQ:FCSC Can Impact Your Portfolio Volatility

2019-06-13 09:50:01 | Savara Plunges on Failure of Late-Stage Study on Molgradex

2019-05-30 08:44:12 | Fibrocell Up on FDA Designation for Gene Therapy Candidate

2019-05-30 08:00:00 | Fibrocell to Present at BIO International Convention 2019

2019-05-29 09:30:01 | Is Fibrocell Science FCSC Stock Outpacing Its Medical Peers This Year?

2019-05-29 08:00:00 | Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB

2019-05-16 10:03:02 | The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business

2019-05-15 09:34:01 | Fibrocell FCSC Miss Estimates for Earnings & Revenues in Q1

2019-05-15 08:11:12 | Small Business Optimism Hits 4-Month High in April: 5 Picks

2019-05-15 07:30:00 | Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights

2019-05-13 09:30:01 | Is Fibrocell Science FCSC Outperforming Other Medical Stocks This Year?

2019-05-13 08:44:12 | Blueprint Medicines BPMC Q1 Earnings & Sales Lag Estimates

2019-05-10 15:27:07 | Global Blood GBT Reports Narrower-Than-Expected Loss in Q1

2019-05-10 14:54:06 | Agenus AGEN Q1 Earnings Beat Estimates, Revenues Miss

2019-05-10 10:11:02 | Spectrum Pharma SPPI Q1 Earnings Lag Estimates, Revenues Nil

2019-05-10 10:00:02 | Puma Biotech PBYI Q1 Earnings Top, Nerlynx Disappoints

2019-05-10 08:34:12 | Intrexon XON Reports In-Line Q1 Loss, Misses on Revenues

2019-05-09 18:17:10 | Horizon Therapeutics' HZNP Q1 Earnings Beat Estimates

2019-05-09 15:21:07 | Amicus' FOLD Earnings & Revenues Miss Estimates in Q1

2019-05-09 15:03:07 | IVERIC bio's ISEE Q1 Loss Narrows, Gene Therapy in Focus

2019-05-09 11:05:03 | Sarepta SRPT Q1 Earnings Top Estimates, Exondys 51 Sales Up

2019-05-09 09:03:01 | Arena Pharmaceuticals' ARNA Loss Widens in Q1 But Stock Up

2019-05-09 08:00:00 | Fibrocell to Host Conference Call and Webcast on Wednesday, May 15, 2019 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

2019-05-09 06:57:10 | AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

2019-05-07 13:51:05 | Mylan's MYL Q1 Earnings Beat Estimates, Revenues Miss

2019-05-07 08:56:12 | Ultragenyx RARE Reports Wider-Than-Expected Loss in Q1

2019-04-30 17:50:09 | Fibrocell Science FCSC Flat As Market Gains: What You Should Know

2019-04-25 09:30:01 | Is Fibrocell Science FCSC Stock Outpacing Its Medical Peers This Year?

2019-04-17 09:14:00 | These 2 Biotech Stocks Are No Longer 'Off the Radar'

2019-04-17 07:48:11 | Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study